Bleichroeder holds 8.21% of Precision Biosciences (DTIL) common stock

Rhea-AI Filing Summary

Bleichroeder LP and related entities have reported a significant ownership position in Precision Biosciences, Inc. They are deemed to beneficially own 1,900,000 common shares, representing 8.21% of the company’s common stock believed to be outstanding as of 12/31/2025.

The shares are held for various advisory clients of Bleichroeder LP, which is a registered investment adviser. Clients have the right to receive dividends and sale proceeds from these securities. The filing states that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Precision Biosciences.

Insights

Equity ownership and governance analyst

Large institutional holder reports an 8.21% passive stake in Precision Biosciences.

Bleichroeder LP, through its advisory role for various clients, reports beneficial ownership of 1,900,000 common shares of Precision Biosciences, equal to 8.21% of the common stock believed outstanding as of 12/31/2025.

The filing is on a Schedule 13G/A, which is the passive ownership format. It explicitly certifies that the securities are held in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.

Because this is an ownership disclosure without stated activist intent or transaction details, it mainly updates the shareholder base picture rather than signaling a strategic shift. Future company filings may further describe any material changes in this ownership level or intentions if they occur.

FAQ

How many Precision Biosciences (DTIL) shares does Bleichroeder beneficially own?

Bleichroeder is deemed to beneficially own 1,900,000 Precision Biosciences common shares. According to the Schedule 13G/A, this stake represents 8.21% of the company’s common stock believed to be outstanding as of December 31, 2025, held for various advisory clients.

What percentage of Precision Biosciences (DTIL) does Bleichroeder’s stake represent?

Bleichroeder’s reported holdings represent 8.21% of Precision Biosciences’ common stock. The Schedule 13G/A states beneficial ownership of 1,900,000 shares, described as 8.21% of the common stock believed to be outstanding as of December 31, 2025, across advisory client accounts.

Who ultimately benefits economically from Bleichroeder’s DTIL shareholdings?

Clients of Bleichroeder LP ultimately benefit from the DTIL shareholdings. The filing explains that Bleichroeder acts as investment adviser to various clients, who have the right to receive and direct the receipt of dividends and sale proceeds associated with the 1,900,000 Precision Biosciences shares.

Is Bleichroeder’s 8.21% DTIL position intended to influence control of Precision Biosciences?

The filing states the DTIL position is not intended to influence control. It certifies that the securities were acquired and are held in the ordinary course of business, not for changing or influencing control, and not in connection with any control-related transaction, other than activities tied to a nomination under Rule 14a-11.

Which entities and individual are listed as reporting persons for the DTIL stake?

The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP, and Andrew Gundlach. The filing lists these parties, with Bleichroeder LP as a registered investment adviser and Gundlach, a United States citizen, signing the certification as President and CEO on February 13, 2026.

What type of SEC filing did Bleichroeder submit for its Precision Biosciences holding?

Bleichroeder submitted an Amendment No. 1 to Schedule 13G for DTIL. This form is used to report beneficial ownership of more than 5% of a class of equity securities on a passive basis, updating the disclosed stake and confirming its ordinary-course investment nature.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PRECISION BIOSCIENCES INC

(Name of Issuer)

Common Shares

(Title of Class of Securities)

74019P207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Bleichroeder LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,900,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,900,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,900,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.21 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Bleichroeder Holdings LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,900,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,900,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,900,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.21 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Andrew Gundlach

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,900,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,900,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,900,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.21 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRECISION BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC 27701
Item 2.
(a)	Name of person filing: Bleichroeder Holdings LLC Bleichroeder LP Andrew Gundlach
(b)	Address or principal business office or, if none, residence: 1345 Avenue of the Americas, 47th Floor New York, NY 10105
(c)	Citizenship: Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA Andrew Gundlach: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 74019P207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See cover page.
(b)	Percent of class: See cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See cover page.
	(ii) Shared power to vote or to direct the vote: See cover page.
	(iii) Sole power to dispose or to direct the disposition of: See cover page.
	(iv) Shared power to dispose or to direct the disposition of: See cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 1,900,000 shares, or 8.21% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. ee Exhibit 99.1
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	02/13/2026

Bleichroeder Holdings LLC

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	02/13/2026

Andrew Gundlach

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	02/13/2026

Exhibit Information

Exhibit 1: Subsidiary Information